THERAPIX BIOSCIENCES LTD Inactive Instrument
Therapix Biosciences Ltd Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0010951403
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - ILa | - |
|
| 11/04 | SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd. | CI |
| 01/04 | SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.35 495.9 112.23 | Sales 2023 | 2.88 1.06T 239.88 | Capitalization | 25.56L 94Cr 21Cr |
|---|---|---|---|---|---|
| Net income 2022 | -20L -74Cr -17Cr | Net income 2023 | -50L -184.08Cr -42Cr | EV / Sales 2022 | 11,45,812 x |
| Net cash position 2022 | 35.47L 130.58Cr 30Cr | Net cash position 2023 | 50L 184.08Cr 42Cr | EV / Sales 2023 | -8,48,893 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-0.34
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
More press releases
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +21.63% | 4.41TCr | |
| +23.16% | 2.27TCr | |
| +18.22% | 1.51TCr | |
| +12.66% | 1.36TCr | |
| +60.18% | 1.33TCr | |
| -8.72% | 684.06Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +15.65% | 562.63Cr |
